Skip to main content

Heparin

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ME Therapeutics
ME TherapeuticsNEW YORK, NY
2 programs
Sodium Heparin UQ subcutaneous drug administrationPHASE_11 trial
Sodium heparin UQ Intravenous drug administrationPHASE_11 trial
Active Trials
NCT03113084SuspendedEst. Oct 2023
NCT03125187SuspendedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ME TherapeuticsSodium Heparin UQ subcutaneous drug administration
ME TherapeuticsSodium heparin UQ Intravenous drug administration

Clinical Trials (2)

NCT03113084ME TherapeuticsSodium Heparin UQ subcutaneous drug administration

Study With Heparin Sodium in Subcutaneous Administration

Start: Aug 2022Est. completion: Oct 2023
Phase 1Suspended
NCT03125187ME TherapeuticsSodium heparin UQ Intravenous drug administration

Study With Heparin Sodium in Intravenous Administration

Start: Feb 2021Est. completion: Nov 2022
Phase 1Suspended

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.